Rein Therapeutics Files 8-K on Operations and Financials
Ticker: RNTX · Form: 8-K · Filed: May 15, 2025 · CIK: 1420565
| Field | Detail |
|---|---|
| Company | Rein Therapeutics, Inc. (RNTX) |
| Form Type | 8-K |
| Filed Date | May 15, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: operations, financials, corporate-action
TL;DR
Rein Therapeutics dropped an 8-K on 5/15/25 covering financials and operations. Formerly Aileron Therapeutics.
AI Summary
Rein Therapeutics, Inc. filed an 8-K on May 15, 2025, reporting on its results of operations and financial condition. The filing also includes financial statements and exhibits. The company was formerly known as Aileron Therapeutics, Inc., with a name change occurring on March 29, 2024.
Why It Matters
This filing provides an update on Rein Therapeutics' financial health and operational status, which is crucial for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This is a routine filing providing operational and financial updates, not indicating any immediate significant risks.
Key Players & Entities
- Rein Therapeutics, Inc. (company) — Registrant
- Aileron Therapeutics, Inc. (company) — Former company name
- May 15, 2025 (date) — Report date
- March 29, 2024 (date) — Date of name change
- 12407 N. Mopac Expy. Suite 250 #390 (address) — Principal Executive Offices
- Austin, Texas (location) — Principal Executive Offices location
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Rein Therapeutics, Inc.'s results of operations and financial condition, and to include financial statements and exhibits.
When was Rein Therapeutics, Inc. formerly known as?
Rein Therapeutics, Inc. was formerly known as Aileron Therapeutics, Inc.
On what date did the company change its name from Aileron Therapeutics, Inc.?
The company changed its name from Aileron Therapeutics, Inc. on March 29, 2024.
What is the principal executive office address of Rein Therapeutics, Inc.?
The principal executive office address of Rein Therapeutics, Inc. is 12407 N. Mopac Expy. Suite 250 #390, Austin, Texas, 78758.
What is the filing date of this 8-K report?
The filing date of this 8-K report is May 15, 2025.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 15, 2025 regarding Rein Therapeutics, Inc. (RNTX).